DR Congo to Launch Second Ebola Vaccine in November

3
389
pharmacy

In three provinces, from November 2019, medical practitioners from Democratic Republic of Congo will commence the use of a second Ebola vaccine to fight the deadly virus, an AFP’s release has stated.

According to the AFP’s report, Dr Jean-Jacques Muyembe, the national anti-Ebola operation leader in the DRC said, it’s time to use the new Ad26-ZEBOV-GP vaccine, manufactured by Johnson & Johnson’s Belgian subsidiary.

Explaining to the citizens, Muyembe said, it will arrive in the Eastern City of Goma, in North Kivu Province, on 18 October and will be in use from the beginning of next month.

DRC’s latest Ebola epidemic, which began in August 2018, has killed 2,144 people, making it the second deadliest outbreak of the virus, after the West Africa pandemic of 2014-2016.

READ
Cholera Outbreak: 10 African Countries Report 26,000 Cases, 660 Deaths

Muyembe said the communes of Majingo and Kahembe had been selected to receive the vaccine as they were considered the epicentres of the epidemic.

DR Congo to Launch Second Ebola Vaccine in November

“We will extend this vaccination to our small traders who often go to Rwanda to protect our neighbours,” he added.

“If it works well, we will expand vaccination in South Kivu and Ituri.”

DR Congo’s eastern provinces of Ituri, North Kivu and South Kivu sit on the borders with Uganda, Rwanda and Burundi.

The Belgian laboratory will send a batch of 200,000 doses to neighbouring Rwanda and 500,000 doses in the DRC, Muyembe said.

More than 237,000 people living in active Ebola transmission zones have received a vaccination produced by the pharma company Merck Sharpe and Dohme since August 8, 2018.

READ
Pharmacy Tower: Join us to Make History, Ohuabunwa, Others Urge Pharmacists

The J&J vaccine had been rejected by DRC’s former health minister Oly Ilunga, who cited the risks of introducing a new product in communities where mistrust of Ebola responders is already high.

But Ilunga’s resignation in July appears to have paved the way for approval of the second vaccine. He currently faces charges that he embezzled funds intended for the fight against Ebola.

In his letter of resignation Ilunga said “actors who have demonstrated a lack of ethics” want to introduce a second vaccine, but did not elaborate.

Muyembe, who took over the Ebola fight in the DRC in July, said “The Johnson & Johnson vaccine has the most science-based data.”

READ
COVID-19: Nigeria Records 339 New Cases, 211 Deaths, 7016 Total

 

3 COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here